EUCTR2014-005544-18-ES进行中（未招募）1 期
A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Completion of study PB-102-F02
- •2. The patient signs informed consent
- •3. Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method. Acceptable methods of contraception include hormonal products, intrauterine device, or male or female condoms. Contraception should be used for 1 month after termination of treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. Pregnant or nursing
- •2. Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient’s compliance with the requirements of the study
研究者
相似试验
进行中（未招募）
1 期
An Extension of the PB-102-F02 study with PRX-102 in adult patients with Fabry Disease.Fabry diseaseEUCTR2014-005544-18-GBProtalix Ltd.16
已完成
1 期
Extension Study of PRX-102 for up to 60 MonthsFabry DiseaseNCT01981720Protalix15
进行中（未招募）
不适用
A multi-center single arm phase II study of MDX-010 BMS-734016 monotherapy in patients with previously treated unresectable stage III or IV melanoma. - NDEUCTR2005-002051-41-ITBRISTOL-M.SQUIBB150
进行中（未招募）
不适用
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma.Revised Protocol 01, incorporating Amendment 02; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06.MelanomaEUCTR2005-002051-41-SEBristol-Myers Squibb International Corporation170
进行中（未招募）
不适用
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV MelanomaRevised Protocol 01, incorporating Amendment 02Estudio multicéntrico, fase II, de un solo brazo de tratamiento con MDX-010 (BMS734016) en monoterapia en pacientes con melanoma Estadio III o IV previamente tratadoMelanomaEUCTR2005-002051-41-ESBristol-Myers Squibb International Corporation170